I would pump the brakes on that one. They will still need to raise cash before the end of next year but needing funds for marketing and distribution is still a ways off.
That being said the bar is very low in showing efficacy in PC given its difficulties to treat. The FDA won't need to see much to get this moving along fairly quickly.
Let's see the results first, but yeah if even moderately positive pancreatic could well be their first marketed indication. The FDA would indeed be under a huge amount of pressure to approve for pancreatic rapidly.